Characterization of the Tautomycin Biosynthetic Gene Cluster from Streptomyces spiroverticillatus Unveiling New Insights into Dialkylmaleic Anhydride and Polyketide Biosynthesis

Tautomycin (TTM) is a highly potent and specific protein phosphatase inhibitor isolated from Streptomyces spiroverticillatus. The biological activity of TTM makes it an important lead for drug discovery, whereas its spiroketal-containing polyketide chain and rare dialkylmaleic anhydride moiety draw attention to novel biosynthetic chemistries responsible for its production. To elucidate the biosynthetic machinery associated with these novel molecular features, the ttm biosynthetic gene cluster from S. spiroverticillatus was isolated and characterized, and its involvement in TTM biosynthesis was confirmed by gene inactivation and complementation experiments. The ttm cluster was localized to a 86-kb DNA region, consisting of 20 open reading frames that encode three modular type I polyketide synthases (TtmHIJ), one type II thioesterase (TtmT), five proteins for methoxymalonyl-S-acyl carrier protein biosynthesis (Ttm-ABCDE), eight proteins for dialkylmaleic anhydride biosynthesis and regulation (TtmKLMNOPRS), as well as two additional regulatory proteins (TtmF and TtmQ) and one tailoring enzyme (TtmG). A model for TTM biosynthesis is proposed based on functional assignments from sequence analysis, which agrees well with previous feeding experiments, and has been further supported by in vivo gene inactivation experiments. These findings set the stage to fully investigate TTM biosynthesis and to biosynthetically engineer new TTM analogs.Tautomycin (TTM)² is a polyketide natural product first isolated in 1987 from Streptomyces spiroverticillatus (1). The structure and stereochemistry of TTM were established on the basis of chemical degradation and spectroscopic evidence (2-4). TTM contains several features not common to polyketide natural products, including a spiroketal group, a methoxymalonate-derived unit, and an acyl chain bearing a dialkylmaleic anhydride moiety. Structurally related to TTM is tautomycetin (TTN), which was first isolated in 1989 from Streptomyces griseochromogenes following the discovery of TTM (5, 6). The structure of TTN was deduced by chemical degradation and spectroscopic analysis (6), and its stereochemistry was established by comparison of spectral data with those of TTN degradation products and synthetic fragments (7). Both TTM and TTN exist as tautomeric mixtures composed of two interconverting anhydride and diacid forms in approximately a 5:4 ratio under neutral conditions (Fig. 1A) (1, 2).Open in a separate windowFIGURE 1.A, structures of TTM and TTN in anhydride or diacid forms, and biosynthetic origin of the dialkylmaleic anhydride by feeding experiments using ¹³C-labeled acetate and propionate. The methoxymalonate-derived unit in TTM is highlighted by the dotted oval. R, polyketide moiety of TTM or TTN. B, selected natural product inhibitors of PP-1 and PP-2A featuring a spiroketal or dialkylmaleric anhydride moiety. C, selected natural products containing a dialkylmaleic anhydride moiety.Early studies of TTM revealed its ability to induce morphological changes in leukemia cells (8). However, it was later realized that TTM is a potent and specific inhibitor of protein phosphatases (PPs) PP-1 and PP-2A (9). PP-1 and PP-2A are two of the four major serine/threonine protein phosphatases that regulate diverse cellular events such as cell division, gene expression, muscle contraction, glycogen metabolism, and neuronal signaling in eukaryotic cells (10-12). Many natural product PP-1 and PP-2A inhibitors are known, including okadaic acid (13), calyculin-A (14), phoslactomycin, spirastrellolide, and cantharidin (15) (Fig. 1B), as well as TTM (16, 17), and TTN (18). They have served as useful tools to study PP-involved intracellular events in vivo and as novel leads for drug discovery (10-12). Among these PP inhibitors, TTM and TTN are unique because of their PP-1 selectivity. Despite their structural similarities, TTM exhibits potent specific inhibition of PP-1 and PP-2A with IC₅₀ values of 22-32 nm and only a slight preference for PP-1 (18). Conversely, TTN shows nearly a 40-fold higher binding affinity to PP-1 (IC₅₀ = 1.6 nm) than to PP-2A (IC₅₀ = 62 nm) (18). Because the major structural differences between TTM and TTN reside in the region distal to the dialkylmaleic anhydride moiety (Fig. 1A), it has been proposed that differences in these moieties might be responsible for the PP-1 selectivity (17-19). Finally, TTN also has an impressive immuno-suppressive activity (20, 21), which is apparently devoid for TTM. Clearly, the structural differences between these two polyketides translate into large, exploitable differences in bio-activities, yet an understanding of the biosynthetic origins of these differences remains elusive.The spiroketal and dialkylmaleic anhydride features of TTM are uncommon for polyketide natural products, as is the methoxymalonate-derived unit (Fig. 1A). Few studies have been carried out for spiroketal biosynthesis, yet it is reasonably common among the phosphatase inhibitors such as calyculin A, okadaic acid, and a few others (Fig. 1B). Less common, but still found in the phosphatase inhibitor cantharidin, as well as TTM and TTN, is the dialkylmaleic anhydride moiety (Fig. 1B); this unit appears in a number of other natural products (Fig. 1C), although the biosynthetic steps leading to this reactive moiety (a protected version of a dicarboxylate) have not been rigorously investigated. Feeding experiments with ¹³C-labeled precursors indicated that the anhydride of TTM and TTN is assembled from a propionate and an as yet undefined C-5 unit (Fig. 1A), which would require novel chemistry for polyketide biosynthesis (22). TTM differentiates itself from all known PP-1 and PP-2A inhibitors by virtue of its unique combination of both the dialkymaleic anhydride and spiroketal functionalities.Multiple total syntheses of TTM and a small number of analogs have been reported, confirming the predicted structure and absolute stereochemistry and facilitating structure-activity relationship studies on PP inhibition and apoptosis induction (19, 23-25). These studies revealed that: (i) the C22-C26 carbon chain and the dialkylmaleic anhydride are the minimum requirements for TTM bioactivity; (ii) the C18-C21 carbon chain and 22-hydroxy group are important for PP inhibition; (iii) the spiroketal moiety determines the affinity to specific protein phosphatases; (iv) the active form is most likely the dicarboxylate; and (v) 3′-epi-TTM exhibits 1,000-fold less activity than TTM. However, taken as a whole, none of the analogs had an improved potency or selectivity for PP-1 inhibition than the natural TTM (19, 22-25). As a result, a more specific inhibitor of PP-1 is urgently awaited to differentiate the physiological roles of PP-1 and PP-2A in vivo and to explore PPs as therapeutic targets for drug discovery.We have undertaken the cloning and characterization of the TTM biosynthetic gene cluster from S. spiroverticillatus as the first step toward engineering TTM biosynthesis for novel analogs (26). We report here: (i) cloning and sequencing of the complete ttm gene cluster, (ii) determination of the ttm gene cluster boundaries, (iii) bioinformatics analysis of the ttm cluster and a proposal for TTM biosynthesis, and (iv) genetic characterization of the TTM pathway to support the proposed pathway. Of particular interest has been the identification of genes possibly related to dialkylmaleic anhydride biosynthesis, the unveiling of the ttm polyketide synthase (PKS) genes predicted to select and incorporate four different starter and extender units for TTM production, and the apparent lack of candidate genes associated with spiroketal formation. These findings now set the stage to engineer TTM analogs for novel PP-1- and PP-2A-specific inhibitors by applying combinatorial biosynthetic methods to the TTM biosynthetic machinery.